MCA
REGN icon

McGuire Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

McGuire Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.87K Hold
3
– – ﹤0.01% 697
2026
Q1 		$2.32K Sell
3
-2
-40% -$1.53K ﹤0.01% 632
2025
Q4 		$3.86K Buy
+5
New +$3.4K ﹤0.01% 571

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

McGuire Capital Advisors's REGN Position: Q2 2026 in Review

McGuire Capital Advisors held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 3 shares worth $1.87K. The position accounts for ﹤0.01% of the portfolio, ranked #697.

McGuire Capital Advisors first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.86K in Q4 2025. 1,330 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • McGuire Capital Advisors held 3 shares of Regeneron Pharmaceuticals worth $1.87K as of Q2 2026.
  • McGuire Capital Advisors left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of McGuire Capital Advisors's portfolio in Q2 2026, its #697 holding.
  • McGuire Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • McGuire Capital Advisors's Regeneron Pharmaceuticals position peaked at $3.86K in Q4 2025.
  • 1,330 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on McGuire Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.